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ABSTRACT: SHIP2 (SH2-domain containing inositol 5-
phosphatase type 2) is a canonical 5-phosphatase, which,
through its catalytic action on PtdInsP3, regulates the PI3K/
Akt pathway and metabolic action of insulin. It is a drug
target, but there is limited evidence of inhibition of SHIP2 by
small molecules in the literature. With the goal to investigate
inhibition, we report a homologous family of synthetic,
chromophoric benzene phosphate substrates of SHIP2 that
display the headgroup regiochemical hallmarks of the
physiological inositide substrates that have proved difficult
to crystallize with 5-phosphatases. Using time-dependent
density functional theory (TD-DFT), we explore the intrinsic
fluorescence of these novel substrates and show how
fluorescence can be used to assay enzyme activity. The TD-DFT approach promises to inform rational design of enhanced
active site probes for the broadest family of inositide-binding/metabolizing proteins, while maintaining the regiochemical
properties of bona f ide inositide substrates.
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In eukaryotic cells, many signaling pathways are regulated bylevels of inositol phosphates (inositides), phosphatidylino-
sitol phosphates (phosphoinositides), and the proteins that are
their cognate binding partners. The balance of these is
controlled by families of kinases and phosphatases that
phosphorylate and dephosphorylate these molecules at specific
positions, designated locants, of the inositol ring.1 SH2-domain
containing inositol 5-phosphatase type 2 (SHIP2) belongs to a
family of phosphatases that hydrolyze the 5-phosphate of
inositides and phosphoinositides. The substrates are known to
include inositol pentakisphosphates (InsP5), tetrakisphos-
phates (InsP4), trisphosphates (InsP3), phosphatidylinositol
3,4,5-trisphosphate (PtdInsP3), and phosphatidylinositol 4,5-
bisphosphate (PtdInsP2).
2
An understanding of how these enzymes function is
important to pathologies such as diabetes and cancer.2
SHIP2 reduces levels of PtdInsP3, while increasing levels of
PtdIns(3,4)P2. Consequently, this enzyme regulates the PI3K/
Akt pathway that is linked to cell proliferation and the
metabolic action of insulin.3,4 SHIP2 is expressed in many cell
types and has additionally been linked to regulation of diverse
cellular processes such as calcium signaling, cytoskeletal
remodeling, protein trafficking, and phagocytosis.2,5 While a
mechanistic explanation of inhibition of PI3-kinases has
underpinned therapeutic interventions in cancer,6,7 therapeutic
inhibition of 5-phosphatases lacks similar foundation.
Previous research for inhibitors of SHIP2 has typically
assayed activity using phosphate release with D-myo-inositol-
1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) or D-myo-phosphati-
dylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3).
8 Thus, Suwa
et al. identified AS1949490 as a novel, small molecule inhibitor
of SHIP2. In the absence of structural data or evidence of
catalytic modification of the inhibitor, the exact mode of
inhibition is not clear, though from an enzymological
perspective the nature of inhibition is competitive with respect
to inositide substrate. It is possible that within the chemical
landscape of inhibition, competitive substrate analog inhibitors
will be found. However, further mechanistic analysis would
require identification of the products of such reactions,
something limited for bona f ide substrates by lack of a suitable
chromophore in these molecules. Alternatively, radiolabeled
substrates could be used, but this would demand complex
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synthetic work and HPLC resolution of substrates and
products.
With a view to finding alternative substrates of 5-
phosphatases that have analytically useful chromophoric
properties, we investigated the benzene polyphosphate
compounds shown in Figure 1. Originally, the benzene
phosphate compounds 1 to 6 were designed as substrate
analogs to substitute as ligands to inositol phosphate binding
proteins/enzymes, enabling crystallographic resolution of
protein−ligand complexes and insight into enzyme inhib-
ition.9,10 While simple benzene phosphates appear not to be
substrates of 5-phosphatases,9−11 compound 7, 3-OH-Bz-
(1,2,4)P3, was synthesized and has been shown by assay of
release of phosphate to be a substrate for type I myo-inositol
1,4,5-triphosphate-5-phosphatase (INPP5A).11 Benzene phos-
phate analogues were also used to uncover mechanistic
information in cocrystallization studies with INPP5B.12
We now show that the chromophoric properties of benzene
phosphates vary depending on the regiochemistry of
substituents around the benzene ring and that several members
of this family have an unanticipated, useful, intrinsic
fluorescence. Alongside conventional spectroscopic measure-
ments, we use time-dependent density functional theory (TD-
DFT) to examine how the regiochemistry modifies the
spectroscopic properties. Compound 6, Bz(1,2,4,5)P4, proved
to be intensely fluorescent, a property potentially explainable
by TD-DFT. It is a tantalizing observation that the four
phosphate groups of this compound are stereochemically
homotopic, remaining indistinguishable even in the chiral
environment of the enzyme active site. Since 5-phosphatases
yield only a single product from Ins(1,3,4,5)P4, should benzene
phosphates be substrates, we expect a single, identifiable
product 8 5-OH-Bz(1,2,4)P3 of the dephosphorylation of
compound 6 Bz(1,2,4,5)P4. Compound 8 5-OH-Bz(1,2,4)P3
was, however, not synthesized, so in the absence of reference
material, we sought to use TD-DFT to predict its fluorescence
with the expectation of being able to use this prediction to
identify whether compound 6 Bz(1,2,4,5)P4 could be a
substrate of SHIP2. We therefore investigated the possibility
that benzene phosphates themselves are substrates for
dephosphorylation by SHIP2 and the chromophoric properties
of this class of molecule might allow construction of assays
complementary to those that employ the measurement of
released inorganic phosphate.
Previously, benzene phosphates have been shown to be
inhibitors of INPP5A,7 INPP5B,12 and SHIP2,8 with
compound 6 Bz(1,2,4,5)P4 yielding IC50 values in single
figures and tens of micromolar range against Ins(1,4,5)P3 and
Ins(1,3,4,5)P4 substrates, tested at 1 and 100 μM concen-
trations, respectively. We also recently described the use of a
fluorescent conjugate of Ins(1,3,4,5,6)P5 (2-FAM-InsP5, Figure
2) as an active site probe of inositol pentakisphosphate 2-
kinase13 and as an intracellular probe.14 Here, combining the
use of two classes of ligand, we show that displacement of 2-
FAM-InsP5 affords an assay of benzene phosphate binding to
SHIP2 (Figure 2 and Table 1).
All six benzene phosphate derivatives chosen displaced 2 nM
2-FAM-InsP5 from SHIP2 with IC50 values in the low
micromolar range, the benzene tetrakisphosphates being
more effective than benzene trisphosphates, with IC50 values
approximately 1 order of magnitude smaller than the
trisphosphates.
Most commonly, 5-phosphatase activity is assayed as the
release of inorganic phosphate from Ins(1,3,4,5)P4 or PtdIns-
(3,4,5)P3. We assayed the ability of SHIP2 to release
phosphate from inositol phosphates and also benzene
phosphates. We tested whether, by virtue of the lower pKa of
the hydroxyl of a theoretical dephosphorylated benzene
phosphate (leaving group),15,16 benzene phosphates might be
Figure 1. Structures of benzene phosphates used in this study.
Figure 2. Displacement of 2-FAM-InsP5 from SHIP2 by benzene
phosphates. The experiments used 2 nM 2-FAM-InsP5 and 1 μM
SHIP2. Results shown as mean of triplicate experiments (results with
standard deviations given in Table 1).
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better substrates than simple inositol phosphate substrate
(Figure 3).
Ins(1,3,4,5)P4 and InsP6 were included as positive and
negative controls, respectively. Phosphate release was
determined with molybdenum blue, using ferrous sulfate as a
reducing agent.17 While slower than the reaction with
Ins(1,3,4,5)P4, phosphatase activity was noted with all
compounds except InsP6, a substrate for phytases
18 but not
for inositol polyphosphate 5-phosphatases. As the benzene
phosphates are poorer substrates than Ins(1,3,4,5)P4, the rate
of dephosphorylation must be influenced by factors other than
just the pKa of the leaving group. In an earlier study,
11 we
postulated that OH groups in the substrate are likely to have a
mechanistic role, showing that during dephosphorylation of
compound 7 3-OH-Bz(1,2,4)P3 by INPP5A, stabilization of
the phenolic OH proton accompanied deprotonation of the
phosphate groups. In order to test this theory, we compared
phosphate release from compound 7 3-OH-Bz(1,2,4)P3 and
compound 4 Bz(1,2,3,4)P4 (Figure S1). The rate determined
for compound 7 3-OH-Bz(1,2,4)P3 was almost twice that
observed for compound 4 Bz(1,2,3,4)P4. However, this rate is
comparable to that observed for compound 5 Bz(1,2,3,5)P4,
suggesting that the regiochemistry of the ring substitution may
also have an influence.
Having gained evidence for binding of benzene phosphates
to SHIP2 and their catalytic processing by SHIP2, we
speculated that the spectroscopic properties of benzene
phosphates might be exploited to follow catalysis. Excitation
and emission scans of acetonitrile solutions of compound 4
Bz(1,2,3,4)P4, compound 5 Bz(1,2,3,5)P4, compound 6
Bz(1,2,4,5)P4, and tryptophan were measured, and the spectral
details compared to those predicted by TD-DFT (Figure 4 and
Tables S1 and S2). Spectral predictions for compound 8 5-
OH-Bz(1,2,4)P3 are included in the table, but the pure
compound was not available to test. The theoretical methods
employ approaches used in TD-DFT studies of trypto-
phan.19,20 A detailed discussion of the TD-DFT methods
and results is included in Supporting Information.
Significantly, on excitation at 280 nm, the measured
fluorescence of compound 6 Bz(1,2,4,5)P4 was 30 times
more intense than that of the next most fluorescent benzene
tetrakisphosphate, compound 5 Bz(1,2,3,5)P4, and approx-
imately 10% of that of tryptophan (Figure 4). These
observations match the trends predicted by TD-DFT (Tables
S1 and S2). The calculations for compound 8 5-OH-
Bz(1,2,4)P3 predict that the excitation maximum of 5-OH-
Bz(1,2,4)P3 is 6 nm greater than that of compound 6
Bz(1,2,4,5)P4, a prediction confirmed by empirical measure-
ment (Figure 5 and Table S1). Similarly, TD-DFT predicts the
emission maximum for compound 8 5-OH-Bz(1,2,4)P3 is 25
nm greater than that of compound 6 Bz(1,2,4,5)P4 (Figure 5
and Table S2).
As TD-DFT predicts that compound 6 Bz(1,2,4,5)P4 and its
hydrolysis product compound 8 5-OH-Bz(1,2,4)P3 show
significant fluorescence intensity, we devised an HPLC
separation that could be used with fluorescence detection for
Table 1. Comparison of Published IC50 Values for Inhibition of 5-Phosphatases by Benzene Phosphates to Experimentally
Determined IC50 Values Found for Displacement of 2-FAM-InsP5 from SHIP2
compound








Bz(1,2,3)P3 14.23 ± 0.1 >1000 86 ± 28 33.5 ± 6.8
Bz(1,3,5)P3 11.25 ± 2.9 16 ± 9
Bz(1,2,4)P3 7.02 ± 0.05 14 ± 9
Bz(1,2,3,4)P4 2.78 ± 0.59 98 ± 16
Bz(1,2,3,5)P4 1.01 ± 0.43 78 ± 50
Bz(1,2,4,5)P4 1.02 ± 0.1 69.3 ± 15.4
10 4 ± 2 6.3 ± 0.8
108.3 ± 20.312
Figure 3. Benzene phosphates as substrates of SHIP2. Compounds
tested at 100 μM. For Ins(1,3,4,5)P4 and InsP6, the concentration of
SHIP2 was 1 μM and for the benzene phosphates, 4 μM, with
triplicate reactions run for 10 min at 30 °C.
Figure 4. Fluorescence spectra of 500 μM Bz(1,2,3,4)P4 (cyan line),
500 μM Bz(1,2,3,5)P4 (green line), 100 μM Bz(1,2,4,5)P4 (blue line),
and 10 μM tryptophan (black dotted line) in acetonitrile. (A)
Excitation scans determined at emission maxima and (B) emission
scans excited at 280 nm.
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benzene phosphates. First, we established separations following
UV absorbance (Figure S2). HPLC resolved all the discrete
benzene trisphosphates and tetrakisphosphates used in this
study. Compound 6 Bz(1,2,4,5)P4 that eluted at approximately
37 min could also be detected by fluorescence with excitation
at 280 nm and emission at 330 nm. In the first instance, we
wanted to use the HPLC method to investigate whether
SHIP2 could convert compound 6 Bz(1,2,4,5)P4 into
compound 8 5-OH-Bz(1,2,4)P3. Therefore, we selected
conditions that would limit the extent of reaction to a
predominant single dephosphorylation. Extended incubation of
100 μM of compound 6 Bz(1,2,4,5)P4 with 100 nM SHIP2
allowed us to monitor the progression of the reaction without
interference from other fluorescent products as judged by
HPLC (Figure 5A). Over a period of 12 h, the fluorescence
intensity of the parent peak at 37 min diminished correlating
with the appearance of an earlier-eluting peak at 30 min
(Figure 5A). As we did not have the assumed product,
compound 8 5-OH-Bz(1,2,4)P3, to confirm the identity of the
peak at 30 min (Figure 5A), we sought confirmation by
recording fluorescence excitation and emission spectra of the
accumulated products (Figures 5B,C).
Samples analyzed in Figure 5A were diluted 100-fold into
acetonitrile, and fluorescence spectra were recorded (Figure
5B,C). As the proportion of the product increased, the red
shifts in the fluorescence spectra increased correspondingly.
After 12 h incubation, the excitation maximum of the assumed
product, compound 8 5-OH-Bz(1,2,4)P3, was 7 nm greater
than that of the starting material (Figure 5B). This compares
favorably to the shift of +6 nm predicted by TD-DFT for
compound 6 Bz(1,2,4,5)P4 converting to compound 8 5-OH-
Bz(1,2,4)P3 (Table S1). The emission maximum of the
product was 25 nm greater than that of the starting material
(Figure 5C). This also compares favorably to the predicted
shift of +25 nm for compound 6 Bz(1,2,4,5)P4 converting to
compound 8 5-OH-Bz(1,2,4)P3 (Table S2). As discussed in
Supporting Information, the predicted transition energies for
excitation and emission differ systematically from the
experimentally determined values so that variations between
compounds can be defined in terms of wavelength shifts. A
similar observation has previously been noted for this type of
TD-DFT analysis.19,20 From the close match between the
predicted and observed wavelength shifts, we can conclude
that compound 8 5-OH-Bz(1,2,4)P3 is formed when
compound 6 Bz(1,2,4,5)P4 is incubated with SHIP2 under
these conditions.
In order to investigate further the effects of SHIP2 on
compound 6 Bz(1,2,4,5)P4, 100 μM of the substrate was
incubated for 2 h with increasing amounts of SHIP2. This
demonstrated that the conversion of compound 6 Bz(1,2,4,5)-
P4 into its first hydrolysis product, compound 8 5-OH-
Bz(1,2,4)P3, is dependent on the SHIP2 concentration and
that compound 6 Bz(1,2,4,5)P4 alone is stable under these
conditions (Figure S3). Longer incubation and use of tandem
UV-fluorescence detection resulted in a more complicated
product profile with peaks of increased absorbance: fluo-
rescence ratio at 30, 25, 23, and 13 min (Figure S4). This is
consistent with successive dephosphorylation generating a
sequence of different hydroxybenzene phosphate compounds
with different elution profiles as observed for inositol
phosphates.21
The change in fluorescence that accompanies the conversion
of substrate to product can be used to develop a real-time
fluorescence-based assay to follow dephosphorylation of
compound 6 Bz(1,2,4,5)P4 by the exemplar 5-phosphatase
SHIP2 (Figure 6). In the absence of competing additives, the
fluorescence intensity at 325 nm reduces, and the maximum
shifts to a longer wavelength as the reaction between SHIP2
and compound 6 Bz(1,2,4,5)P4 progresses (Figure 6A). Figure
6B traces how the emission intensity at 325 nm (the maximum
for compound 6 Bz(1,2,4,5)P4) decreases with time. It also
shows how this decrease is affected by additives that are
Figure 5. (A) HPLC analysis of reaction of Bz(1,2,4,5)P4 (100 μM)
incubated with SHIP2 (100 nM) at 16 °C for 0 h (blue line), 10 h
(amber line), and 12 h (red line). Substrate and products were
detected by fluorescence (excitation at 280 nm, emission at 330 nm).
(B,C) Fluorescence of the same samples diluted 100-fold in
acetonitrile. SHIP2 (100 nM) alone shown as a dark green line on
the baseline: (B) excitation scans with emission at 330 nm and (C)
emission scans excited at 280 nm.
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reported to be substrates or inhibitors of SHIP2 activity. The
rate of the intensity decrease slows down considerably in the
presence of the natural substrate Ins(1,3,4,5)P4, which, as
shown in Figure 3, is 10 times more active in terms of
phosphate release than any of the benzene phosphates. In the
presence of the SHIP2 inhibitor AS1949490, there is an initial
decrease in fluorescence intensity that matches that of the
reaction with no additives indicating that, in the initial stages
under these conditions, we are not seeing inhibition of SHIP2
activity with compound 6 Bz(1,2,4,5)P4. This experiment is
not an exhaustive analysis of the substrates competing for
SHIP2 activity but serves to demonstrate the utility of benzene
phosphate fluorescence in this context.
While there is much to take account of when designing such
an experiment, we have proved the utility of TD-DFT to select
from a regioisomeric family of benzene tris- and tetraki-
sphosphates for the compound with the best fluorescent
properties to monitor 5-phosphatase, specifically SHIP2,
activity. Interestingly, benzene phosphates appear to undergo
successive dephosphorylations with SHIP2, in contrast to the
single 5-dephosphorylation of inositol phosphate substrates. By
judicious choice of a symmetrical tetrakisphosphate and careful
titration of enzyme, we were able to limit the extent of reaction
to a predominant single dephosphorylation. Interestingly,
toward the end of the experiment shown in Figure 6A there
is a slight shift to shorter wavelength again, most likely
reflecting further dephosphorylation of the 5-OH-Bz(1,2,4)P3
product.
To explore further the catalytic flexibility engendered in
phosphate-substituted benzenes, we also sought to define the
products of successive dephosphorylation of the more weakly
fluorescent compound 4, Bz(1,2,3,4)P4 (Figure S5), for which
a number of potential dephosphorylation products are
available. Accordingly, we included compound 7 3-OH-
Bz(1,2,4)P3 and the newly synthesized compounds 9 1,2-Di-
OH-Bz(3,4)P2 and 10 1,3-Di-OH-Bz(2,4)P2 in our analysis
(full details and structures of these compounds are given in
Supporting Information). We did not detect the accumulation
of compound 7, 3-OH-Bz(1,2,4)P3 from compound 4
Bz(1,2,3,4)P4. This does not rule out its production or that
of 1-OH-Bz(2,3,4)P3 as there is the possibility that the first
product of hydrolysis is rapidly dephosphorylated to Di-OH-
BzP2 products. Indeed, compound 9 1,2-Di-OH-Bz(3,4)P2 =
3,4-Di-OH-Bz(1,2)P2 was generated by SHIP2 from com-
pound 4 Bz(1,2,3,4)P4 (Figure S4) and, from Figure S1, we
can see that compound 7 3-OH-Bz(1,2,4)P3 is a better
phosphate-releasing substrate than compound 4 Bz(1,2,3,4)P4.
Consistently, SHIP2 action on compound 7 3-OH-Bz(1,2,4)P3
yielded multiple products including compound 9 1,2-Di-OH-
Bz(3,4)P2 = 3,4-Di-OH-Bz(1,2)P2, but not compound 10 1,3-
Di-OH-Bz(2,4)P2 = 2,4-Di-OH-Bz(1,3)P2 (Figure S4). [2,3-
Di-OH-Bz(1,4)P2 was not available to test.] The intricacies of
this analysis demonstrate further the advantages of a planned
approach to selecting substrates with the most suitable
properties for probing selected mechanisms of protein activity.
To summarize, with interest in the utility of benzene
phosphates as ligands of diverse inositide/phosphoinositide-
binding proteins/enzymes, we have shown that, uniquely
among characterized ligands of 5-phosphatases, benzene
phosphates have the properties of bona f ide substrate analogs.
Indeed, benzene tris- and tetrakisphosphates are inhibitors of
Type I and Type II inositol polyphosphate 5-phosphatases,9,12
while compound 4 Bz(1,2,3,4)P4 is a tight binding ligand of
the PH domain of PKB/Akt.22 Compound 6 Bz(1,2,4,5)P4 is
an inhibitor of SHIP210 and a structure was solved for a binary
complex with INPP5B.12 Here we show that benzene
phosphates are surrogate substrates of the canonical 5-
phosphatase SHIP2 by virtue of their regiochemistry. This
mimics well the stereoisomerism but not enantiomerism of
inositides and phosphoinositides. Clearly these compounds
could find utility with a range of inositol phosphate
phosphatases beyond 5-phosphatases, e.g., 3-phosphatases
typified by PTEN or 4-phosphatases such as SopB. The
demonstration that they are substrates and can be used for
real-time assays affords great opportunity for the study of
allosteric regulation of catalytic activity by ligand binding to
distal domains of the full-length protein.
Because of its relatively strong absorption and fluorescence
emission, compound 6 Bz(1,2,4,5)P4 is shown to be a
promising spectroscopic probe for inositol 5-phosphatase(s).
It may also be of use for proteins lacking catalytic activity since,
as demonstrated, it is a good ligand of inositol phosphate-
binding sites. Beyond this, the combination of TD-DFT and
enzymological approaches could direct the synthesis of new
probes for the study of specific aspects of protein structure and
function. For real time assays, designed to screen potential
inhibitors of protein activity, there is opportunity to design
chromophores with enhanced, perhaps further red-shifted,
fluorescence. Spectral separation from tryptophan, either in
Figure 6. (A) Change in fluorescence of compound 6 Bz(1,2,4,5)P4
(100 μM) incubated with SHIP2 (1 μM) at 23 °C recording emission
scans excited at 280 nm over a period of 2 h. (B) Change in emission
intensity at 325 nm with time for compound 6 Bz(1,2,4,5)P4
incubated with SHIP2; with no other additives (dark blue line),
with Ins(1,3,4,5)P4 (50 μM) (peach line), and with SHIP2 inhibitor
AS1949490 (100 μM) (light blue line).
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excitation and/or emission, might enable polarization-based
approaches to inhibitor screening of inositol phosphate-
metabolizing enzymes as we have described with 2-FAM-
InsP5 for IPK1,
13 but without the potential constraints of bulky
fluorophore substituents. Probes might be synthesized to retain
the ligand coordination of bona f ide substrates and/or might
afford a range of binding constants tailored for particular
experimental scenarios, cf. ion-sensing fluorescent probes.
Thus, we envisage our methods will enable prediction and
testing of poly-substituted benzenes that retain the regiochem-
istry of a favored ligand while building in the spectroscopic
opportunity of substitution with other functionalities. The
diversification of simple aryl ligands to include other
functionalities may further find use as structure-stabilizing
ligands enabling crystallization of recalcitrant inositol-related
protein targets.12 In summary, there is wide-ranging potential
in this field for the application of TD-DFT to aid decisions
over probe synthesis and experiment design.
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salt); 3-OH-Bz(1,2,4)P3, 3-hydroxybenzene 1,2,4-trisphos-




1,4-bisphosphate; BzP, benzene phosphate; Bz(1,2,3)P3,
benzene 1,2,3-trisphosphate; Bz(1,2,4)P3, benzene 1,2,4-tri-
sphosphate; Bz(1,3,5)P3, benzene 1,3,5-trisphosphate; Bz-
(1,2,3,4)P4, benzene 1,2,3,4-tetrakisphosphate; Bz(1,2,3,5)P4,
benzene 1,2,3,5-tetrakisphosphate; Bz(1,2,4,5)P4, benzene
1,2,4,5-tetrakisphosphate; EDTA, ethylenediamine tetra-acetic
acid; HEPES, 4-(2-hydroxyethyl)-1-piperazineethane sulfonic
acid; His, histidine; HOMO, highest occupied molecular
orbital; HPLC, high-pressure liquid chromatography; IC50,
half-maximal inhibitory concentration; INPP5A, type I inositol
5-phosphatase; INPP5B, type II inositol 5-phosphatase;
INPP5E, inositol polyphosphate 5-phosphatase E; Ins(1,4,5)-
P3, inositol 1,4,5-trisphosphate; Ins(1,3,4,5)P4, inositol 1,3,4,5-
tetrakisphosphate; LUMO, lowest unoccupied molecular
orbital; OCRL-1, Lowe oculocerebrorenal syndrome protein
(INPP5F); PKB, Protein Kinase B; PtdIns(3,4)P2, phospha-
tidylinositol 3,4-bisphosphate; PtdIns(4,5)P2, phosphatidylino-
sitol 4,5-bisphosphate; PtdIns(3,4,5)P3, phosphatidylinositol
3,4,5-trisphosphate; SYNJ1, synaptojanin-1; SYNJ2, synapto-
janin-2; SHIP1, SH2-domain containing inositol 5-phospha-
tase type 1; SHIP2, SH2-domain containing inositol 5-
phosphatase type 2; TCEP, tris(2-carboxyethyl) phosphine;
TD-DFT, time-domain density functional theory; TEV,
Tobacco Etch Virus
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